Report
Thomas Vranken

mdxhealth FIRST LOOK: 1H24 results continue impressive topline growth

In line with previously reported preliminary results, mdxhealth's 1H24 results feature a strong +32% y/y uptake in revenues, while cash burn gradually comes down. Management reiterates its recently upped $ 85-87m FY24 revenue guidance and it still foresees adjusted EBITDA profitability by 1H25. We see mdxhealth as a uniquely positioned player in the urology diagnostics space, and reiterate a $ 6.0 TP and Buy rating.
Underlying
MDXHEALTH

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch